Point72 Asset Management
VIRX

Point72 Asset Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Point72 Asset Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-85,714
Closed -$2.16M – 1313
2019
Q3 		$2.16M Buy
85,714
+45,714
+114% +$1.32M 0.01% 581
2019
Q2 		$1.02M Buy
+40,000
New +$1.55M 0.01% 768
2014
Q3 		– Sell
-2,231
Closed -$3.06M – 790
2014
Q2 		$3.06M Buy
+2,231
New +$2.59M 0.02% 520

Other funds holding VIRX

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Point72 Asset Management's VIRX Position: Q4 2019 in Review

Point72 Asset Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2019, closing a stake of 85,714 shares — an estimated $2.16M sold.

Point72 Asset Management first reported a position in VIRX in Q2 2014 and held it in 3 quarters. The position peaked at $3.06M in Q2 2014. 44 funds tracked by Wall St. Rank hold VIRX as of Q4 2019.

  • Point72 Asset Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Point72 Asset Management sold 85,714 Viracta Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $2.16M.
  • Point72 Asset Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2014 and held it in 3 quarters.
  • Point72 Asset Management's Viracta Therapeutics, Inc. Common Stock position peaked at $3.06M in Q2 2014.
  • 44 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Point72 Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.